Sigyn Therapeutics, Inc. (SIGY): Total Liabilities
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$4.67M
As of 2024-12-31
$6.05M
As of 2025-09-30
+68.6%
3-year compound annual growth
n/m
5-year compound annual growth
+26.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $4.67M | +25.1% | 2025-04-15, Balance as of period end |
| 2023-12-31 | $3.73M | +67.0% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $2.24M | +129.4% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $974.8K | +63.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $594.9K | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | $910 | -100.0% | 2021-04-06, Balance as of period end |
| 2018-12-31 | $4.58M | +9.9% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $4.16M | n/a | 2019-04-01, Balance as of period end |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $1.51M | +226.0% | 2016-03-30, Balance as of period end |
| 2014-12-31 | $462.8K | n/a | 2016-03-30, Balance as of period end |